Efficacy and safety of the freeze-dried cultured human keratinocyte lysate, LyphoDerm™ 0.9%, in the treatment of hard-to-heal venous leg ulcers

• Published in: Wound repair and regeneration 2005-03, Vol.13 (2), p.138-147
• Main Authors: Harding, Keith G., Krieg, Thomas, Eming, Sabine A., Flour, Mieke L.F., Jawien, Arkadiusz, Cencora, Andrzej, Kaszuba, Andrzej, Noszcyk, Wojciech, Willems, Peter, Deene, Andy De, Joos, Evelyne, Waele, Peter De, Delaey, Bernard
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Bandages; Bandages, Hydrocolloid; Cells, Cultured; Female; Freeze Drying; Humans; Keratinocytes; Male; Middle Aged; Skin, Artificial; Time Factors; Treatment Outcome; Varicose Ulcer - physiopathology; Varicose Ulcer - therapy; Wound Healing
• ISSN: 1067-1927; 1524-475X
• DOI: 10.1111/j.1067-1927.2005.130204.x

LyphoDermTM (XCELLentis, Belgium) is an end‐sterilized, freeze‐dried lysate from cultured allogeneic epidermal keratinocytes, formulated into a hydrophilic gel. Its efficacy and safety were evaluated, in combination with standard care (hydrocolloid dressing and compression therapy), in 194 patients suffering from hard‐to‐heal (lasting more than 6 weeks and not responding to conventional therapy) venous leg ulcers. Two control groups received standard care, with or without vehicle, respectively. Patients had a median age of 67.5 years and the majority were females (61%). The median duration of the ulcer was 43 weeks and in 39% of the subjects it had been present for more than 1 year. Thirty‐eight percent of the patients in the standard care + LyphoDermTM group had complete ulcer healing within 24 weeks (primary end point) compared to 27% of patients in the standard care + vehicle pooled groups (P = 0.114) in the “as treated” intent‐to‐treat cohort (37% vs. 27% in the “as randomized intent‐to‐treat cohort; p = 0.137). In the subgroup of patients with enlarging ulcers, the difference between the two groups was significant (30% vs. 11%; p = 0.024 in the “as treated” intent‐to‐treat cohort and 31% vs. 9%; p = 0.005 in the “as randomized” intent‐to‐treat cohort). LyphoDermTM was well tolerated and safe, and no differences in the frequency of adverse events were noted between the treatment groups. Although the primary objective of the study was not achieved, the exploratory analysis carried out in patients with enlarging ulcers suggests that LyphoDermTM could offer a new prospect for the treatment of patients with venous ulcers that may prove to be a significant adjunct to the overall provision of care.